Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
47.94%
Operating Margin
26.67%
Net Margin
24.36%
Efficiency Metrics
Revenue per Expense Ratio
1.36
R&D as % of Revenue
12.15%
Earnings Quality
EBITDA Margin
36.90%
Income Tax Rate
8.95%
EPS
4.6600000000
Balance Sheet Analysis
Current Ratio
3.17
Cash Ratio
1.63
Working Capital
$8.08B
Debt to Equity
0.17
Debt to Assets
11.97%
Equity Ratio
68.41%
Cash Flow Analysis
Operating Cash Flow Ratio
34.66%
Free Cash Flow Ratio
8.42%
CapEx to Revenue
26.24%
Dividends Paid
$223.00M
Stock Buybacks
$346.00M
Total Shareholder Returns
$569.00M
Cash Position Change
-1.10%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 5.43%
Increased R&D investment by 41.41%
Detailed Growth Metrics
Core Performance
Revenue
7.18%
Net Income
6.34%
EPS
-2.31%
Operating Income
1.70%
Operational Efficiency
R&D Expenses
41.41%
SG&A Expenses
15.55%
Operating Cash Flow
7.40%
Free Cash Flow
-29.01%
Balance Sheet Health
Assets
16.51%
Debt
23.37%
Book Value per Share
25.08%
Inventory
4.45%
Shareholder Returns
Dividends per Share
5.43%
Shares Outstanding
-0.23%
Long Term Trends
3Y Revenue/Share
67.48%
5Y Revenue/Share
78.05%
3Y Dividend/Share
31.43%
5Y Dividend/Share
2.77%